Biotech entity
pharma is the sole category represented across all 1 tracked stories. Excel Lactated Ringers Injection is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. B. Braun Medical Inc. appears in 1 tracked Biotech story from August 21, 2026.
Last mentioned: 2d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Excel Lactated Ringers Injection is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. B. Braun Medical Inc. appears in 1 tracked Biotech story from August 21, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering B. Braun Medical Inc.. Shared-story counts are live from our verified record — not editorial picks.
Recalled lot expiration date
Lot J4H077 was labeled with an expiration date of November 30, 2026, meaning unexpired units could still be in circulation if not quarantined.
Recall posted on FDA website
The FDA website posts B. Braun's company announcement alerting healthcare providers and the public to the recall.
Voluntary recall issued
B. Braun Medical Inc. voluntarily recalls lot J4H077 after identifying particulate matter, including cellulose cotton fibers, wood fiber, and polystyrene.
Distribution window ends
The recalled lot J4H077 completes its distribution period after approximately one month.
Distribution of recalled lot begins
B. Braun distributes Excel Lactated Ringers Injection, 1,000 mL lot J4H077 to hospital-level facilities nationally and in Canada.
A single-lot recall of B. Braun's Excel Lactated Ringers Injection highlights how cellulose, wood fiber, and polystyrene contamination in parenteral products can create serious embolic and systemic risks. Pharmaceutical quality teams should examine the contamination source and regulatory implications closely.
B. Braun Medical Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
